Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference. The conference, scheduled for June 4, 2026, at 2:35 p.m. EDT in New York, will feature a discussion on the company's pipeline and strategic direction. The event will be webcast live, with a replay available through the Events & Presentations section of the company's investor relations website. For more details, the full press release is available at https://ibn.fm/1QdP7.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the significant unmet need for individuals suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape by introducing NSAs that provide durable improvements in mental health.
The company's lead candidate, HLP003, is a proprietary NSA currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD). It has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). Additionally, Helus Pharma is developing HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder (GAD). The company also maintains an extensive research portfolio of investigational NSAs.
The Jefferies Global Healthcare Conference provides a platform for Helus Pharma to engage with the investment community and discuss its clinical programs. The fireside chat with CEO Eric So is expected to cover the company's recent milestones, including the progress of its Phase 3 trial for HLP003 and the potential implications of its Breakthrough Therapy Designation.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For company updates and more information, visit www.helus.com or follow the team on social media platforms. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
